José Igor Gomes Da Silva

José Igor Gomes Da Silva

Instituto de Ciências Biomédicas (ICB), UFRJ, Rio de Janeiro, Brazil
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
MRMomtchilo Russo
Momtchilo Russo
MCMaria Cássia Jacintho Mendes Correa
Maria Cássia Jacintho Mendes Correa
BLBruna B. Lins
Bruna B. Lins
VKVictor Kersten
Victor Kersten
PFPaulo C. A. Pernambuco Filho
Paulo C. A. Pernambuco Filho
LMLuciana Mirotti
Luciana Mirotti
Mucosal vaccination appears to be suitable to protect against SARS-CoV-2 infection. In this study, we tested an intranasal mucosal vaccine candidate for COVID-19 that consisted of a cationic liposome containing a trimeric SARS-CoV-2 spike protein and CpG-ODNs, a Toll-like receptor 9 agonist, as an adjuvant. In vitro and in vivo experiments indicated the absence of toxicity following the intranasal administration of this vaccine formulation. First, we found that subcutaneous or intranasal vaccination protected hACE-2 transgenic mice from infection with the wild-type (Wuhan) SARS-CoV-2 strain, as shown by weight loss and mortality indicators. However, when compared with subcutaneous administration, the intranasal route was more effective in the pulmonary clearance of the virus and induced higher neutralizing antibodies and anti-S IgA titers. In addition, the intranasal vaccination afforded protection against gamma, delta, and omicron virus variants of concern. Furthermore, the intranasal vaccine formulation was superior to intramuscular vaccination with a recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 spike glycoprotein (Oxford/AstraZeneca) in terms of virus lung clearance and production of neutralizing antibodies in serum and bronchial alveolar lavage (BAL). Finally, the intranasal liposomal formulation boosted heterologous immunity induced by previous intramuscular vaccination with the Oxford/AstraZeneca vaccine, which was more robust than homologous immunity.

29 May 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
José Igor Gomes Da SilvaJosé Igor Gomes Da Silva
José Igor Gomes Da Silva
VKVictor Kersten
Victor Kersten
LDLivia Mendonça Munhoz Dati
Livia Mendonça Munhoz Dati
BLBruna B. Lins
Bruna B. Lins
TTTania R. Tozzeto-Mendoza
Tania R. Tozzeto-Mendoza
RODRIGO A. P. MARTINSRODRIGO A. P. MARTINS
RODRIGO A. P. MARTINS
Neurological and ocular manifestations were reported in COVID-19 patients and in SARS-CoV-2 infected animal models. However, the effects of SARS-CoV-2 variants of concern (VoC) on the eyes and the retina remain unclear. Here, we investigate the cellular and molecular consequences of SARS-CoV-2 VoC infection on the eye and retina in mice and hamsters. Infection with the ancestral SARS-CoV-2 and the Gamma VoC induced a subtle increase in the eye volume of K18-hAce2 mice, but no morphological alteration was observed in hamsters’ eyes. Evaluation of the ocular tropism revealed that distinct SARS-CoV-2 VoC reached the eye globe, but not the retina of K18-hAce2 mice. In contrast, SARS-CoV-2 variants are detected in the hamsters’ retina during both acute infection and after disease recovery. Despite the presence of viral RNA, no inflammation was observed in the hamster retina, as evidenced by unchanged microglial cell density and unaltered gene expression of several immune mediators. Altogether, these findings indicate a limited impact of SARS-CoV-2 variants on the eye and retina.

9 October 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
MRMomtchilo Russo
Momtchilo Russo
MCMaria Cássia Jacintho Mendes Correa
Maria Cássia Jacintho Mendes Correa
BLBruna Bezerra Lins
Bruna Bezerra Lins
VKVictor Kersten
Victor Kersten
PFPaulo C. A. Pernambuco Filho
Paulo C. A. Pernambuco Filho
LMLuciana Mirotti
Luciana Mirotti
Mucosal vaccination appears to be suitable to protect against SARS-CoV-2 infection. In this study, we tested an intranasal mucosal vaccine candidate to COVID-19 constituted of a cationic liposome containing a trimeric SARS-CoV-2 spike protein and CpG-ODNs, a Toll-like receptor 9 agonist, as adjuvant. In vitro and in vivo experiments indicated the absence of toxicity following the intranasal administration of this vaccine formulation. First, we found that subcutaneous or intranasal vaccination protected hACE-2 transgenic mice from infection with the wild-type (Wuhan) SARS-CoV-2 strain, as shown by weight lost and mortality indicators. However, when compared to the subcutaneous administration, the intranasal route was more effective in the pulmonary clearance of the virus and induced higher neutralizing antibodies and anti-S IgA titers. In addition, the intranasal vaccination afforded protection against gamma, delta and omicron virus variants of concern. Furthermore, the intranasal vaccine formulation was superior to intramuscular vaccination with a recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 spike glycoprotein (Oxford/AstraZeneca) in terms of virus lung clearance and production of neutralizing antibodies in serum and bronchial alveolar lavage (BAL). Finally, the intranasal liposomal formulation boosted heterologous immunity induced by previous intramuscular vaccination with the Oxford/AstraZeneca vaccine that was more robust than homologous immunity.